Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Au Chun Kwok Alan	2. Issuer Name and Ticker or Trading Symbol Cellular Biomedicine Group, Inc. [ CBMG ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) C/O CELLULAR BIOMEDICINE GROUP, INC., 9605 MEDICAL CENTER DRIVE, SUITE 100	3. Date of Earliest Transaction (MM/DD/YYYY) 2/19/2021
(Street) ROCKVILLE, MD 20850 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option	$15.62	2/19/2021 ⁽¹⁾		D			4000	11/7/2015	11/7/2024	Common Stock	4000	⁽²⁾	0	D
Non-Qualified Stock Option	$20.00	2/19/2021 ⁽³⁾		D			5056	11/8/2016	2/9/2023	Common Stock	5056	⁽⁴⁾	0	D
Non-Qualified Stock Option	$20.00	2/19/2021 ⁽⁵⁾		D			2060	11/6/2016	3/25/2023	Common Stock	2060	⁽⁴⁾	0	D
Non-Qualified Stock Option	$13.35	2/19/2021 ⁽⁶⁾		D			9789	6/2/2017	12/28/2026	Common Stock	9789	⁽²⁾	0	D
Non-Qualified Stock Option	$10.80	2/19/2021 ⁽⁷⁾		D			12056	4/28/2018	4/28/2027	Common Stock	12056	⁽²⁾	0	D
Non-Qualified Stock Option	$19.71	2/19/2021		D			7213	4/26/2019	5/18/2028	Common Stock	7213	⁽²⁾	0	D
Non-Qualified Stock Option	$17.00	2/19/2021 ⁽⁸⁾		D			2238	4/24/2020	5/15/2029	Common Stock	2238	⁽²⁾	0	D
Non-Qualified Stock Option	$17.89	2/19/2021 ⁽⁹⁾		D			1390	4/24/2020	11/11/2029	Common Stock	1390	⁽²⁾	0	D
Non-Qualified Stock Option	$14.68 ⁽¹⁰⁾	2/19/2021		D			6348	4/23/2021 ⁽¹¹⁾	4/25/2030	Common Stock	6348	⁽²⁾	0	D

Explanation of Responses:
(1)	As previously reported on the Issuer's Form DEF 14A Definitive Proxy Statement filed on March 12, 2018, on November 7, 2014 the Reporting Person was granted an option to purchase up to 4,000 shares of common stock, all of which vested and became fully exercisable on November 7, 2015.
(2)	Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 11, 2020, by and among Cellular Biomedicine Group, Inc. (the "Company"), CBMG Holdings ("Parent") and CBMG Merger Sub Inc. ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly-owned subsidiary of Parent (the "Merger"). The Merger became effective on February 19, 2021 (the "Closing Date"). Pursuant to the Merger Agreement, at the effective time of the Merger, each stock option was cancelled and exchanged for the right to receive an amount in cash equal to (A) the total number of shares of common stock subject to such stock option multiplied by (B) the excess, if any, of the per share merger consideration of $19.75 over the exercise price of the stock option.
(3)	As previously reported on the Issuer's Form DEF 14A Definitive Proxy Statement filed on March 12, 2018, on February 9, 2016 the Reporting Person was granted an option to purchase up to 5,056 shares of common stock, all of which vested and became fully exercisable on November 8, 2016.
(4)	Pursuant to the Merger Agreement, on the Closing Date each stock option with an exercise price greater than the per share merger consideration of $19.75 was cancelled for no consideration or payment.
(5)	As previously reported on the Issuer's Form DEF 14A Definitive Proxy Statement filed on March 12, 2018, on March 25, 2016 the Reporting Person was granted an option to purchase up to 2,060 shares of common stock, all of which vested and became fully exercisable on November 6, 2016.
(6)	As previously reported on the Issuer's Form DEF 14A Definitive Proxy Statement filed on March 12, 2018, on December 28, 2016 the Reporting Person was granted an option to purchase up to 9,789 shares of common stock, all of which vested and became fully exercisable on June 2, 2017.
(7)	As previously reported on the Issuer's Form DEF 14A Definitive Proxy Statement filed on March 12, 2018, on April 28, 2017 the Reporting Person was granted an option to purchase up to 12,056 shares of common stock, all of which vested and became fully exercisable on April 28, 2018.
(8)	As previously reported on the Issuer's Form DEF 14A Definitive Proxy Statement filed on April 29, 2020, on May 15, 2019 the Reporting Person was granted an option to purchase up to 3,133 shares of common stock, 895 shares of which were forfeited on July 3, 2019 when the Reporting Person elected to change the ratio of his cash and option compensation. The remaining 2,238 stock options vested and became fully exercisable on April 24, 2020.
(9)	As previously reported on the Issuer's Form DEF 14A Definitive Proxy Statement filed on April 29, 2020, on November 11, 2019 the Reporting Person was granted an option to purchase up to 1,390 shares of common stock, all of which vested and became fully exercisable on April 24, 2020.
(10)	The exercise price of this option to purchase shares of common stock was previously reported erroneously as $14.65 in the Reporting Person's Form 4 filed on April 28, 2020.
(11)	In connection with the Merger, unvested options were accelerated and vested in full at the effective time of the Merger.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Au Chun Kwok Alan C/O CELLULAR BIOMEDICINE GROUP, INC. 9605 MEDICAL CENTER DRIVE, SUITE 100 ROCKVILLE, MD 20850	X